Samumed selected for 7 presentations in 5 therapeutic areas at ACR 2016
Samumed has been selected for seven presentations in five therapeutic areas at the ACR Annual Meeting. The company's novel Wnt pathway inhibitor compounds show potential for treating diseases such as chronic tendinopathy, degenerative disc disease, scleroderma, osteoarthritis, and psoriasis.